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Abstract
 .  .Platelet-derived growth factor PDGF stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate Ptd InsP via2
 .  .phospholipase C-g1 PLC-g1 in Swiss 3T3 cells. Treatment of cells with the protein kinase C PKC inhibitor Ro-31-8220
greatly decreased PDGF-induced tyrosine phosphorylation of PLC-g1, but paradoxically enhanced the production of
 .inositol phosphates InsPs . The inhibitor also caused an increase of PDGF receptor tyrosine phosphorylation at later times.
The changes in phosphorylation of the receptor were correlated with alterations in PLC-g1 translocation to the particulate
fraction. Thus, although activation of PLC-g1 was associated with phosphorylation of the receptor and translocation of the
enzyme to the particulate fraction, it was dissociated from its tyrosine phosphorylation. A non-receptor-associated, cytosolic
tyrosine kinase also was found to phosphorylate PLC-g1 in a PDGF-dependent manner, but was not inhibited by
Ro-31-8220 in vitro. PKC depletion by phorbol ester treatment decreased the tyrosine phosphorylation of PLC-g1 induced
by PDGF and slowed the translocation of PLC-g1, but Ro-31-8220 produced further effects. The effect of Ro-31-8220 to
enhance the production of InsPs could not be attributed to inhibition of PKC since InsPs production with PDGF was
decreased in PKC-depleted cells and a stimulatory effect of the inhibitor was still evident. Interestingly, Ro-31-8220
decreased the radioactivity in phosphatidylinositol and increased that in phosphatidylinositol 4-phosphate and PtdInsP in2
w3 xcells labeled with myo H inositol. The increased synthesis of PtdInsP could contribute to the increased production of2
InsPs induced by Ro-31-8220. In summary, these results support the conclusion that the activation of PLC-g1 in response to
PDGF requires autophosphorylation of the receptor and membrane association of PLC-g1, but not phosphorylation of the
enzyme. Furthermore, the effects of Ro-31-8220 on the tyrosine phosphorylation and activity of PLC-g1, and on PtdInsP2
synthesis cannot be attributed to inhibition of PKC. q 1997 Elsevier Science B.V. All rights reserved.
Abbreviations: PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PKC, protein kinase C; PLC,
phosphoinositide-hydrolyzing phospholipase C; PtdInsP , phosphatidylinositol 4,5-bisphosphate; InsPs, inositol phosphates; PMA,2
4b-phorbol 12-myristate 13-acetate; bIM, bis-indolylmaleimide; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
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1. Introduction
 .Phosphoinositide-specific phospholipase C PLC
w xisozymes 1 mediate the effects of several hormones
and growth factors. PLC catalyzes the hydrolysis of
 .phosphatidylinositol 4,5-bisphosphate PtdInsP ,2
generating two intracellular second messengers, inosi-
w x w xtol trisphosphate 2 and diacylglycerol 3 . The regu-
lation of PLC has been well studied and different
isoforms of PLC are regulated by different mecha-
w xnisms 1,4 . PLC-b isoforms are activated by seven-
w xtransmembrane-domain receptors via G-proteins 5,6
and PLC-g isoforms are activated by tyrosine
kinase-containing receptors such as platelet-derived
 .growth factor receptor PDGFR and epidermal
 .growth factor receptor EGFR and also by certain
w xsoluble tyrosine kinases 1,7 .
The regulation of PLC-g1 by EGF and PDGF has
been studied in various cell types. Ligand binding to
the receptors for these growth factors stimulates the
intrinsic tyrosine kinase, leading to tyrosine phospho-
rylation of the receptor itself and of other cellular
w xsubstrates 8–10 . Certain tyrosine residues that are
phosphorylated as a result of receptor autophospho-
rylation then act as specific binding sites for src
 .homology SH2 domains present in PLC-g1 and
w xother signaling proteins 11,12 .
The stable association of PLC-g1 with the acti-
vated receptor is necessary for activation of PLC-g1
w x11,13–16 . Since PLC-g isoforms are also substrates
w xfor the tyrosine kinase activity of the receptors 17,18 ,
it has also been suggested that tyrosine phosphoryla-
wtion of PLC-g1 is involved in its activation 17,19–
x21 . This is supported by the finding that substitution
of Phe at Tyr-783 in PLC-g1 blocked activation of
w xthe expressed enzyme by PDGF 22 . However, tyro-
sine phosphorylation did not alter the catalytic activ-
ity of PLC-g1 measured in vitro under standard
w xconditions 22,23 . It has also been observed that the
purified EGFR increased the activity of non-
tyrosine-phosphorylated PLC-g1 to a much greater
w xextent than the phosphorylated form in vitro 24 .
Therefore, it is not clear what role tyrosine phospho-
rylation by the receptor plays in the activation of
PLC in growth factor-stimulated cells.
Here we report that tyrosine phosphorylation of
PLC-g1 in response to PDGF was almost abolished
by pretreatment of Swiss 3T3 cells with the PKC
inhibitor Ro-31-8220, while inositol phosphates In-
.sPs production was enhanced. By studying further
the effect of Ro-31-8220 on the kinetics of receptor
autophosphorylation and PLC-g1 translocation to the
particulate fraction, we propose that physical associa-
tion of PLC-g1 and the receptor is enough to in-
crease the catalytic activity of the enzyme and that
phosphorylation of the enzyme is not required. On
the basis of studies of inositol phospholipid changes,
we also propose that the enhancement of InsPs pro-
duction by Ro-31-8220 is due in part to increased
polyphosphoinositide synthesis. Furthermore, the ef-
fects of Ro-31-8220 cannot be attributed to inhibition
of PKC.
2. Materials and methods
2.1. Materials
Penicillin, streptomycin, and Hepes-buffered Dul-
 .becco’s modified Eagle’s medium DMEM with L-
glutamine were purchased from GibcorBRL. Fetal
bovine serum, bovine serum albumin fraction V,
.sterilized 35% solution for cell culture , inositol
phospholipid standards, and 4b-phorbol 12-myristate
 .13-acetate PMA were from Sigma. Bis-indolylma-
 .leimide bIM was from CalBiochem. PDGF BrB
 .human recombinant was from Boehringer
Mannheim. Ro-31-8220, was kindly provided by
Roche Products Ltd. Welwyn Garden City, Hertford-
. w 32 xshire, U.K. . ECL detection kit, g- P adenosine-
X  . w 3 x5 -triphosphate 6000 Cirmmol and myo- 2- H in-
 .ositol 17 Cirmmol were from Amersham Life Sci-
ence. Monoclonal anti-phosphotyrosine antibody
 .PY-20 , anti-PLC-g1 antibody and anti-PDGFR an-
tibody were obtained from ICN, Upstate Biotechnol-
ogy Inc., and Santa Cruz respectively. Liquid scintil-
 .lation cocktails Ready-Safe and AG 1-X8 ion ex-
change resin were from BioRad.
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2.2. Cell culture
Swiss 3T3 fibroblasts were maintained in Hepes-
buffered DMEM with 4 mM L-glutamine supple-
 .mented with 10% vrv fetal bovine serum, 100 units
penicillinrml and 100 mg streptomycinrml at 378C
in a humidified, 5% CO -controlled incubator. For all2
experiments, cells were grown on 10 cm dishes for
 .1–2 days to subconfluency 60–70% . The medium
was then replaced with a low serum medium DMEM
containing 1% fetal bovine serum, 0.5% bovine serum
.albumin, and antibiotics for 2 days to allow the cells
to become quiescent. To label the cells, the relevant
radioactive chemicals were added during the last
overnight incubation period.
2.3. Measurement of total inositol phosphates
Cells were serum-starved as described above and
w3 xlabeled with 0.5 mCirml of myo- H inositol for 20
h in inositol-free DMEM containing 0.5% bovine
serum albumin and antibiotics. The cells were then
washed three times with the serum-free medium con-
taining 0.5% bovine serum albumin, and preincu-
bated in the medium for 1 h at 378C prior to incuba-
tion with PDGF. During the last 10 min of the
preincubation period, LiCl was added in a final con-
centration of 20 mM. Cells were then treated with 50
ngrml of PDGF BrB at 378C for the indicated
times. Incubations were terminated, the cells were
lysed, and total InsPs were measured as described
w xpreviously 25 .
2.4. Measurement of inositol phospholipids
Swiss 3T3 fibroblasts were maintained, starved
w3 xand labeled with 10 mCirml of myo- H inositol for
20 h as described above. The cells were washed three
times with serum-free medium containing 0.5% serum
albumin. Cells were then incubated for 2 h with
 .either vehicle 0.1% Me SO or 10 mM Ro-31-8220.2
The incubations were terminated by washing the cells
 .with phosphate-buffered saline PBS . Lipids were
 .extracted in CHCl :MeOH:PBS 1:2:1 and washed3
with 2.4 N HCl. The organic phase was further
 .washed with MeOH:1NHC1 1:1 . The extracted
lipids were dried, resuspended in CHCl and sepa-3
rated by thin layer chromatography on Silica Gel 60
plates impregnated with 1% oxalate using a develop-
ing solvent of CHCl racetonerMeOHracetic3
 .acidrH O 12:45:39:36:24 . Radiolabeled phospho-2
inositides were localized by comigration with PtdIns,
PtdIns 4-P, and PtdInsP standards added to each2
sample.
2.5. Measurement of protein tyrosine phosphorylation
Quiescent cells were washed and preincubated in
the presence or in the absence of 10 mM Ro-31-8220
for 1 h. After treatment with 50 ngrml of PDGF for
the indicated times, cells were lysed in 2 mlrdish of
lysis buffer 50 mM Tris-HCl, pH 7.5, containing 2
mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM
4-amidinophenylmethanesulfonyl fluoride, 100
mgrml leupeptin, 25 mgrml aprotinin, 50 mM b-
.glycerophosphate and 0.1 mM sodium orthovanadate
for 30 min on a rocker at 48C. The lysates were spun
in an Eppendorf centrifuge and the same amount of
soluble protein was analyzed by SDS-PAGE. Proteins
containing phosphotyrosine were detected by West-
ern blotting against anti-phosphotyrosine antibodies
 .PY-20 .
2.6. Cytosolic protein tyrosine kinase phosphoryla-
tion of PLC-g1
Quiescent cells were prepared as above, and treated
with 50 ngrml of PDGF for 5 min. The cells were
then washed three times with PBS, scraped, trans-
ferred into 10 ml of PBS and centrifuged at 200=g
for 5 min. The cell pellet was resuspended in 0.3 ml
of homogenization buffer 50 mM Tris-Cl, pH 7.5,
2.0 mM EDTA, 1.0 mM EGTA, 1 mM DTT, 0.1 mM
phenylmethanesulfonyl fluoride, 5 mgrml leupeptin,
50 mM b-glycerophosphate and 0.1 mM sodium
.orthovanadate and homogenized with a Dounce ho-
 .mogenizer followed by sonication 3 bursts of 5 s .
The lysates were centrifuged at 105 000=g for 1 h
and the cytosol assayed for tyrosine phosphorylation
of PLC-g1. The standard assay contained 20 mM
Hepes pH 7.2, 25 mM MgCl , 5 mM MnCl , 1 mM2 2
DTT, 0.1 mM phenylmethanesulfonyl fluoride, 0.1 M
b-glycerophosphate, 0.1 mM sodium orthovanadate,
100 mM ATP, 90 ml of cytosol and the indicated
concentration of inhibitor in a final volume of 180
ml. The reaction was allowed to proceed for 30 min
at 378C, terminated by the addition of 1 ml of ice
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cold RIPA Buffer CPBS; pH 7.0, 0.2 mM sodium
orthovanadate, 50 mM ß-glycerophosphate 1% NP40,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM EDTA
and 0.1 mM PMSF. PLC-g1 was then immunopre-
cipiated, and Western blotted against anti PY-20, anti
PLC-g1 and anti-PDGFR.
2.7. Protein tyrosine kinase assay
PDGF-stimulated cells were processed as de-
scribed in the preceding section, with the addition of
0.3% Triton X-100 to the lysis buffer, and cen-
trifuged in an Eppendorf centrifuge. The activity of
protein tyrosine kinase was determined by the incor-
32 w 32 xporation P from g- P ATP into angiotensin II as
w xdescribed by Yu and Glazier 26 in the presence of
the indicated inhibitors in a final volume of 50 ml.
2.8. Translocation of phospholipase C-g1
Quiescent cells were washed and preincubated in
DMEM containing 0.5% bovine serum albumin for 1
h at 378C. Cells were then treated with or without 50
ngrml of PDGF for the indicated times. To measure
the translocation of PLC-g1 to the particulate frac-
tion, the cells were washed once with ice-cold PBS
and then scraped in 2 mlrdish of homogenization
buffer containing 25 mM Tris, pH 7.5, 2 mM EDTA,
0.5 mM EGTA, 1 mM DTT, 0.1 mM 4-amidinophen-
ylmethanesulfonyl fluoride, 100 mgrml leupeptin, 25
mgrml aprotinin, 50 mM b-glycerophosphate and
0.1 mM sodium orthovanadate. The cells were ho-
mogenized and fractionated into cytosolic and partic-
w xulate fractions as described by Ha and Exton 27 .
In order to determine PLC-g1 translocation to the
cytoskeleton, fractions soluble and insoluble in 0.2%
.Triton X-100 were prepared as described by Yang et
w xal. 28 with minor modifications. After the cells were
 .washed once with ice-cold cytoskeleton CSK buffer
 .containing 0.1 M Pipes pH 6.9 , 2 M glycerol, 1 mM
EGTA, and 1 mM Mg acetate, the soluble proteins
were extracted for 5 min with cold CSK buffer
containing 0.2% Triton X-100, 100 mgrml of leu-
peptin, 20 mgrml of aprotinin, 0.1 mM sodium
orthovanadate, and 0.1 mM 4-amidinophenylmethane
sulfonyl fluoride, 50 mM NaF, and 10 mM b-
glycerolphosphate. The insoluble fraction containing
the cytoskeletal proteins was extracted into RIPA
buffer 1% deoxycholate, 1% Triton X-100, 0.1%
SDS, 0.15% NaCl, 1 mM EDTA in 50 mM Tris-HCl,
.pH 7.5 , containing the same concentrations of in-
hibitors of proteases and phosphatases as in the CSK
buffer, to extract the soluble proteins.
Equivalent amounts of protein from each fraction
were analyzed by 7.5% SDS-PAGE and Western
blotted against monoclonal anti-PLC-g1 antibodies.
Proteins containing phosphotyrosine in each fraction
were also detected by Western blotting against PY20
antibodies as described before. To detect the immune
complexes, the ECL system Amersham Life Sci-
.ence was used.
3. Results
3.1. Effects of Ro-31-8220 on tyrosine phosphoryla-
tion in PDGF-stimulated Swiss 3T3 fibroblasts
In order to examine the involvement of PKC in
signaling by PDGF, we tested the effect of the selec-
Fig. 1. Effect of PKC inhibitor, Ro-31-8220, on tyrosine phos-
phorylation stimulated by PDGF in Swiss 3T3 cells. Quiescent
 .  .cells, preincubated with either vehicle 0.1% Me SO y or 102
 .mM of Ro-31-8220 q for 1 h, were treated with 50 ngrml of
PDGF BrB for the indicated times. Cell were lysed and the same
amount of protein from each lysate was analyzed by 7.5%
SDS-PAGE. Tyrosine phosphorylation in response to PDGF
stimulation was determined by Western blot analysis against
 .anti-phosphotyrosine antibodies PY-20 . The positions of the
 .PDGF receptor PDGFR and 145 kDa protein are indicated. A
representative experiment of three is shown.
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w xtive PKC inhibitor, Ro-31-8220 29 , on the tyrosine
phosphorylation of the PDGFR and other proteins.
Cells were preincubated in the absence or presence of
10 mM of the inhibitor for 1 h prior to PDGF
stimulation for various times. Lysates were analyzed
by Western blotting with anti-phosphotyrosine anti-
 .body PY20 . As shown in Fig. 1, PDGF stimulated
the tyrosine phosphorylation of several proteins in-
cluding the 180 kDa PDGFR. There was a rapid
increase within 1 min and then a gradual decrease
between 5 and 30 min. Ro-31-8220 caused a large
reduction of tyrosine phosphorylation of a 145 kDa
 .protein at all times 1–30 min , but caused a later
increase in the phosphorylation of the PDGF receptor
 .Fig. 1 and data not shown, see also Fig. 5 .
3.2. Identification of 145 kDa protein as PLC-g1
Since the 145 kDa protein had the same molecular
mass as PLC-g1 and this enzyme is a known sub-
w xstrate of PDGFR tyrosine kinase 15,17,19–21,23 ,
we tested if the 145 kDa protein was PLC-g1. Cells
were exposed to PDGF for 5 min after treatment with
or without the inhibitor, lysed, immunoprecipitated
and subjected to Western blotting with PLC-g1 mon-
oclonal antibodies. As shown in Fig. 2, the tyrosine-
phosphorylated 145 kDa protein migrated identically
with PLC-g1. In each case, equal amounts of PLC-g1
were detected in the immunoprecipitates, but only the
precipitates from the PDGF-treated cells showed sig-
nificant tyrosine phosphorylation. Furthermore, al-
Fig. 2. Effect of Ro-31-8220 on tyrosine phosphorylation of PLC-g1 in PDGF-stimulated Swiss 3T3 cells. Quiescent cells were
 .  .  .  .preincubated in the absence y or in the presence q of Ro-31-8220 and treated with either medium y or 50 ngrml of PDGF q
for 5 min. PLC-g1 was immunoprecipitated from the cell lysate using PLC-g1 monoclonal antibodies and analyzed by 7.5% SDS-PAGE.
The same amounts of protein in the total cell lysates and in the supernatants after immunoprecipitation were applied together with the
immunoprecipitates. In the upper panel, the amount of PLC-g1 recovered from immunoprecipitation was identified by Western blotting
 .using PLC-g1 monoclonal antibodies. Tyrosine phosphorylation of PLC-g1 in response to PDGF stimulation lower panel was
 .determined by Western blot analysis against anti-phosphotyrosine antibodies PY-20 . A representative experiment of two is shown.
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though the inhibitor decreased tyrosine phosphoryla-
tion of PLC-g1, it did not affect the amount of the
enzyme found in the lysates or immunoprecipitates.
The tyrosine-phosphorylated 145 kDa protein disap-
peared from the supernatant after immunoprecipita-
tion of PLC-g1 and became associated with the
 .immunoprecipitate Fig. 2 . These results established
that the 145 kDa protein was PLC-g1 and that its
tyrosine phosphorylation was attenuated by Ro-31-
8220. The tyrosine phosphorylation of PLC-g1 in
w xresponse to PDGF was also attenuated by bIM 30
 .another selective inhibitor of PKC data not shown .
3.3. Lack of effect of Ro-31-8220 on soluble tyrosine
kinase acti˝ity
To see if the reduction in tyrosine phosphorylation
of PLC-g1 was due to direct inhibition of a tyrosine
kinase, PDGF-stimulated cell lysates were tested for
Ro-31-8220 inhibition of tyrosine phosphorylation of
angiotensin II. As shown in Fig. 3A, the inhibitor
 .0.01–10 mM had no significant effect on tyrosine
phosphorylation of the substrate, while genistein was
clearly inhibitory. This result was further checked by
incubating cytosol from PDGF-treated cells in the
presence or absence of ATP or Ro-31-8220 and then
subjecting it to immunoprecipitation and Western
blotting with antibodies against PLC-g1, PDGFR and
P-tyrosine. PLC-g1 was phosphorylated upon the
 .addition of ATP Fig. 3B and the phosphorylation
 .was decreased by genistein data not shown . How-
ever, Ro-31-8220 did not alter the tyrosine phospho-
 .rylation of PLC-g1 Fig. 3B , supporting the conclu-
sion that it does not inhibit a soluble tyrosine kinase.
3.4. Effect of Ro-31-8220 on translocation of PLC-g1
induced by PDGF
PLC-g1 is predominantly a cytosolic protein and
growth factor treatment of cells elicits its redistribu-
w xtion to the membrane fraction 31 . The effect of
Ro-31-8220 on the translocation of PLC-g1 is shown
in Fig. 4. In control cells, less than 10% of the total
PLC-g1 was present in the particulate fraction. When
cells were treated with PDGF, there was a rapid
membrane association of PLC-g1 which continued
up to 5 min and then gradually decreased, presum-
ably due to PDGFR down-regulation. In the presence
Fig. 3. Effect of inhibitors on PDGF-stimulated tyrosine kinase
activity and phosphorylation of PLC-g1. Quiescent cells were
treated with 50 ngrml of PDGF for 5 min, washed in PBS, lysed
and cytosol isolated. A. Tyrosine kinase activity of the lysate was
w 32 xassayed by the incorporation of g- P ATP into angiotensin II in
the presence of increasing concentrations of either Ro-31-8220 or
 .genistein. Control assays received vehicle 0.1% Me SO instead2
of inhibitor. Results, given as percent of control, are the average
of two experiments performed in duplicate. B. Aliquots of cy-
 .  .tosol were incubated with q or without y ATP or Ro-31-
8220. PLC-g1 was immunoprecipitated after incubation for 30
min. Tyrosine phosphorylation was determined by Western blot
 .analysis against anti-P-tyrosine antibodies PY-20 . A representa-
tive experiment of two is shown.
of Ro-31-8220, PLC-g1 translocated to the particu-
late fraction with slower kinetics, but the association
with this fraction continued to increase through 30
min. The time course of translocation of PLC-g
correlated with that of PDGFR tyrosine phosphoryla-
tion in either the presence or absence of Ro-31-8220
 .Fig. 1 .
Because cytoskeletal proteins have been shown to
interact with both PtdInsP and PLC-g1 in response2
w xto growth factors 32 , the effect of Ro-31-8220 on
PLC-g1 translocation to the cytoskeleton was also
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 .Fig. 4. PDGF-induced translocation of PLC-g1 to the particulate fraction. Quiescent cells preincubated with either vehicle 0.1% Me SO2
 .  .  .y or 10 mM of Ro-31-8220 q for 1 h were treated with 50 ngrml of PDGF for the indicated times. Control cells 0 received the
serum-free medium instead of PDGF and there were no differences in the distribution of PLC between the time points. Cell homogenates
 .  .were fractionated into cytosolic C and particulate P fractions and analyzed by 7.5% SDS-PAGE and Western blotting against PLC-g1
monoclonal antibodies as described in Section 2. A representative experiment of three is shown.
 .investigated. As shown in Fig. 5 upper panel , PLC-
g1 rapidly translocated to the cytoskeleton upon
PDGF stimulation of cells, but the translocation was
not affected by the PKC inhibitor. Since tyrosine
kinases have been implicated in the translocation of
w xPLC-g1 to the cytoskeleton 28,33 , we also exam-
ined the distribution of tyrosine phosphorylated PLC-
g1 between the soluble and cytoskeleton fractions.
w xUnlike the study of Yang et al. 27 , the tyrosine
phosphorylated PLC-g1 was found in both the solu-
 .Fig. 5. PDGF-induced translocation of PLC-g1 to the cytoskeleton. The quiescent cells preincubated with either vehicle 0.1% Me SO2
 .  .  .y or 10 mM of Ro-31-8220 q for 1 h were treated with 50 ngrml of PDGF for the indicated times. Control cells 0 received the
serum free-medium instead of PDGF and there were no differences in the distribution of PLC between the time points. Cells were washed
 .with CSK buffer containing 0.2% Triton X-100 soluble fraction and the insoluble proteins were extracted in RIPA buffer as described in
 .Section 2 CSK fraction . The same amounts of protein were analyzed by 7.5% SDS-PAGE and Western blotting against either
 .  .  .anti-PLC-g1 antibodies upper panel or phosphotyrosine antibodies PY-20 lower panel as described in Section 2. A representative
experiment of two is shown.
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Fig. 6. PDGF-stimulated tyrosine phosphorylation of PLC-g1 in
PKC-depleted Swiss 3T3 cells. The subconfluent quiescent cells
 .were preincubated with either vehicle Control or 500 nM of
 .TPA PKC-depleted for 36 h and were treated with 50 ngrml of
PDGF for the indicated times. Cells were lysed and the same
amount of protein from each lysate was analyzed by 6% SDS-
PAGE. Tyrosine phosphorylation in response to PDGF was deter-
mined by Western blot analysis against anti-phosphotyrosine
antibodies. A representative experiment of three is shown.
 .ble and cytoskeleton fractions Fig. 5, lower panel .
Ro-31-8220 markedly decreased the tyrosine phos-
phorylation of PLC-g1 in both soluble and cyto-
skeleton fractions.
3.5. In˝ol˝ement of PKC in the regulation of PLC-g1
by PDGF
To test whether the effect of Ro-31-8220 on tyro-
sine phosphorylation of PLC-g1 was due to the
inhibition of PKC isozymes, these enzymes were
depleted from the cells by prolonged exposure to
PMA. As shown in Fig. 6, PMA treatment reduced
the tyrosine phosphorylation of PLC-g1, but not to
 .the extent induced by Ro-31-8220 Fig. 1 . Further-
more, addition of the inhibitor to the depleted cells
 .produced a further large decrease data not shown .
PKC depletion also altered the kinetics of PDGF-
induced translocation of PLC-g1 to the particulate
 .fraction Fig. 7 in a manner similar to that of
 .Ro-31-8220 Fig. 4 . However, addition of Ro-31-
8220 to the PKC-depleted cells produced further
 .changes Fig. 7 . These data indicate that inhibition
of PKC can only partly explain the effects of Ro-31-
8220 on PLC-g1 tyrosine phosphorylation and
translocation.
3.6. Effects of Ro-31-8220 and PKC depletion on
inositol phosphate production induced by PDGF
It has been suggested that the activation of PLC-g1
by growth factors requires its tyrosine phosphoryla-
w xtion 21,23 . Since Ro-31-8220 attenuated tyrosine
phosphorylation of PLC-g1, we tested its effect on
Fig. 7. PDGF-induced translocation of PLC-g1 to the particulate fraction in PKC-depleted Swiss 3T3 cells. After PKCs were depleted as
described in the legend of Fig. 6, the cells were treated with or without 10 mM Ro-31-8220 and with 50 ngrml of PDGF for the indicated
times. Cell homogenates were fractionated into cytosolic and particulate fractions and analyzed by 7.5% SDS-PAGE and Western blotting
against PLC-g1 monoclonal antibodies as described in Section 2. A representative experiment of two is shown.
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InsPs production in cells prelabeled for 20 h with
w3 x  .myo H inositol and stimulated by PDGF Fig. 8 .
Contrary to expectations, PDGF-stimulated InsPs
production in the presence of 20 mM LiCl was much
greater in the presence of Ro-31-8220 than in its
 .absence Fig. 8 . The effect was most pronounced at
 .later incubation times 30–60 min .
To test whether or not these results were due to a
decrease in PKC activity, the effects of PKC deple-
tion on PDGF-induced InsPs production were tested.
In contrast to what was seen with Ro-31-8220, PKC
depletion significantly decreased InsPs accumulation
 .Fig. 9 . Furthermore, in the PKC-depleted cells,
addition of Ro-31-8220 was still able to increase
PDGF-stimulated InsPs production approximately 2-
 .fold, as seen in the control cells Fig. 10 . These data
thus illustrate that the effects of Ro-31-8220 on InsPs
production cannot be explained in terms of PKC
inhibition.
Fig. 8. Effect of Ro-31-8220 on PDGF-stimulated inositol phos-
phate production in Swiss 3T3 cells. Subconfluent, serum-starved
w3 xcells were labeled with 0.5 mCirml of myo- H inositol overnight
and the cells were preincubated and stimulated with either vehi-
 .  .cle circles or 50 ngrml of PDGF triangles for the indicated
w3 xtimes in the presence of 20 mM LiCl. H InsPs accumulation
was determined as described in Section 2. Data are presented as
the quotient of InsPs divided by Ins plus InsPs, and represent
means for a representative of 3 experiments performed in dupli-
cate.
Fig. 9. Effect of PKC depletion on PDGF-stimulated inositol
phosphate accumulation. Cells were pretreated for 24 h with 500
 .nM PMA PKC-depleted, closed symbols and cells were then
w3 xlabeled with 0.5 mCirml of myo- H inositol overnight. Control
 .  .cells open symbols received the vehicle 0.1% Me SO instead2
of PMA. The cells were preincubated and treated with either
 .  .serum-free medium circles or 50 ngrml of PDGF triangles for
w3 xthe indicated times in the presence of 20 mM LiCl. H InsPs
accumulation was determined as described in Section 2. Data are
presented as the quotient of InsPs divided by Ins plus InsPs, and
represent means for a typical experiment performed in duplicate.
3.7. Effects of Ro-31-8220 on inositol phospholipid
le˝els
In order to explain the unexpected stimulatory
effect of Ro-31-8220 on InsPs production, the inosi-
Table 1
Effects of Ro-31-8220 on the labeling of inositol phospholipids
w3 xin cells pre-incubated with myo H inositol
PtdIns PtdInsP PtdInsP2
% of total radioactivity
Vehicle 82.3, 80.1 8.3, 11.6 7.3, 6.9
qRo-31-8220 65.3, 66.0 19.2, 16.0 15.5, 18.1
qbIM 84.3, 83.8 9.1, 11.6 6.6, 4.6
w3 xSwiss 3T3 cells were incubated with 10 mCirml of myo H in-
 .ositol for 20 h and then for 2 h with either vehicle 0.1% Me SO2
10 mM Ro-31-8220, or 1 mM bIM. Lipids were extracted and
separated as described in Section 2. Data are plotted as % of total
radioactivity in inositol phospholipids. The results from two
separate experiments are shown.
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Fig. 10. Effect of Ro-31-8220 on PDGF-stimulated inositol phos-
phate accumulation in PKC-depleted Swiss 3T3 cells. Cells were
 .pretreated for 36 h with either Me SO Control or 500 nM PMA2
 .PKC-depleted , and were labeled with 0.5 mCirml of myo-
w3 xH inositol during the last overnight incubation. The cells were
 .  .preincubated with either Me SO y or Ro-31-8220 q , and2
treated with either serum-free medium or 50 ngrml of PDGF for
w3 x30 min in the presence of 20 mM LiCl. H InsPs accumulation
was determined as described in Section 2. Data are presented as
the quotient of InsPs divided by Ins plus InsPs, and represent
means for a typical experiment performed in duplicate.
tol phospholipids were measured in cells incubated in
the presence and absence of this inhibitor after la-
w3 xbelling with myo H inositol for 20 h. Table 1 shows
w3 xthat Ro-31-8220 caused a decrease in H PtdIns and
w3 x w3 xincreases in H PtdInsP and H PtdInsP , but with2
 .no change in total radioactivity data not shown . The
findings are consistent with an enhancement of the
net synthesis of the two polyphosphoinositides from
PtdIns. To see if the changes in inositol phospho-
lipids were due to inhibition of PKC, the effects of
w xanother potent PKC inhibitor bIM 30,34 were tested.
As shown in Table 1, this compound was without
effect.
4. Discussion
PDGF is very efficacious in stimulating hydrolysis
w xof PtdInsP in Swiss 3T3 cells 34 . It is generally2
accepted that autophosphorylation of the PDGFR is
required for its physical interaction with PLC-g1
w x11,12,17 , which is a prerequisite step for activation
w xof the enzyme 11,13,15,16 . As expected, we ob-
served an increase in autophosphorylation of the
 .PDGFR in response to PDGF Figs. 1 and 2 , and
translocation of a portion of cytosolic PLC-g1 to the
 .particulate fraction Fig. 4 . These responses were
accompanied by an increase in InsPs production Fig.
.8 . When cells were treated with the growth factor for
 .longer times 15 min or more , these effects gradually
decreased, presumably due to PDGFR down-regu-
lation. In agreement with the findings of others
w x28,35 , we also observed that PLC-g1 translocated
to the Triton X-100-insoluble fraction, which in-
 .cludes the cytoskeleton Fig. 5 upper panel .
One of the striking observations of the present
study is the large dissociation induced by Ro-31-8220
between the tyrosine phosphorylation and activity of
PLC-g1 in cells treated with PDGF. However, the
relationship between the tyrosine phosphorylation and
activity of this enzyme has never been clearly estab-
lished. Because PLC-g1 is rapidly phosphorylated on
tyrosine residues after PDGF treatment, it has often
been suggested that this phosphorylation is involved
w xin its activation 13,17,19,20,23 . On the other hand,
it has been reported that the activity of tyrosine-phos-
phorylated PLC-g1 is not significantly different from
that of the unphosphorylated enzyme, when measured
using artificial membranes containing PtdInsP2
w x22,23 . Another possibility is that the tyrosine phos-
phorylation of PLC-g in vivo may cause activation
w xby releasing a putative negative regulator 22,36 or
by providing accessibility of the enzyme to its sub-
strate, for example by overcoming the inhibitory
effect of proteins such as profilin, which bind to the
substrate and inhibit its hydrolysis by unphospho-
w xrylated PLC-g1 37,38 . In contrast to the foregoing,
there is evidence that tyrosine phosphorylation of
PLC-g1 has a negative effect on its activity because
it decreases its association with the membrane frac-
w xtion 39 .
Although our results indicate that tyrosine phos-
phorylation of PLC-g1 is not associated with activa-
tion, they do support the concept that membrane
association is correlated with activation. Furthermore,
as shown in Figs. 4 and 5, Ro-31-8220 had minimal
effects on the translocation of PLC-g1 to the mem-
brane fraction or cytoskeleton, consistent with view
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that physical association of the enzyme with these
fractions does not require its tyrosine phosphoryla-
tion.
w x w xKypta et al. 40 and Park et al. 41 have sug-
gested that non-receptor tyrosine kinases may be
involved in the phosphorylation of PLC-g1 in vivo.
Studies on the translocation of PLC-g1 to the cyto-
skeleton have also indicated the involvement of solu-
w xble tyrosine kinases 33 . Furthermore, Nakanishi et
w xal. 42 have demonstrated that PLC-g1 is associated
with, and phosphorylated by, viral and cellular src
kinases. However, Ro-31-8220 did not inhibit the
phosphorylation of PLC-g1 by a soluble tyrosine
 .kinase s in lysates prepared from cells stimulated
 .with PDGF Fig. 2B .
PLC-g1 possesses several phosphorylation sites
w xincluding Y771, Y783 and Y1254 22,43 . Studies of
point mutations at these sites have demonstrated that
phosphorylation of Y783 and Y1254 is essential for
regulation of PLC-g1 in vivo while phosphorylation
w xof Y771 is not required 23 . When Y771 was mu-
tated, InsPs production was actually enhanced, sug-
gesting that phosphorylation of this residue might be
involved in down-regulation of PLC activity. Since
Ro-31-8220 almost completely blocked tyrosine
 .phosphorylation of PLC-g1 Figs. 1, 2 and Figs. 5 ,
it is assumed that it caused loss of phosphate at all 3
tyrosine residues. How enzyme activity was enhanced
by PDGF under these conditions remains obscure.
In several cell lines, PKC activation inhibits recep-
tor-coupled formation of InsPs reviewed in Ref.
w x. w x44 through down-regulation of receptors 45 and
perhaps other mechanisms. However, there is little
evidence of down-regulation of the PDGFR by PKC
w x34,46,47 in comparison to what is observed for the
 w x.EGFR for Refs. see 48 . Rhee and associates have
reported that PKC can directly phosphorylate PLC-
w xg1, but without an activity change 36 . With respect
to PMA treatment in vivo, phosphorylation of the
enzyme was not observed with PC12, C6Bu1 and
w xNIH 3T3 cells 44 , but was seen in Jurkat T-cells,
where it was associated with decreased tyrosine phos-
w xphorylation and inactivation of the enzyme 49 .
The actions of Ro-31-8820 on PLC-g1 in the
present study can only partly be attributed to inhibi-
tion of PKC. Ro-31-8220 and PKC depletion both
decreased PDGF-induced tyrosine phosphorylation of
PLC-g1, but the effect of Ro-31-8220 was much
greater and was still evident in the PKC-depleted
cells. This indication of another mechanism of action
of Ro-31-8220 was reinforced by the divergent ac-
tions of Ro-31-8220 and PKC down-regulation on
InsPs production which indicated another PKC-inde-
pendent effect of the inhibitor.
Although the possibility remains that the effects of
 .Ro-31-8220 are mediated by a PKC isozyme s that
is not down-regulated by phorbol ester treatment, this
seems unlikely. As shown previously, Swiss 3T3
cells contain only the a-, d-, e-, and z-isoforms of
PKC and all of these, except the z-isoform, are
w xdown-regulated by phorbol ester treatment 50 . simi-
larly, Ro-31-8220 and bIM inhibit the a-, d- and
e-isoforms, but have only minimal effects on PKCz
 .34 . Thus the PKC-inhibitors and down-regulation
have similar effects on the different PKC isoforms,
and would be expected to produce the same changes
in PLC-g1 phosphorylation and activity, and in
PtdInsP synthesis, if PKC inhibition was their only2
mechanism of action.
The increased InsPs formation induced by PDGF
 .in the presence of Ro-31-8220 Figs. 8 and 10 was
more pronounced at later incubation times 30–60
.min . The increased association of the enzyme with
the particulate fraction at these incubation times Figs.
.5 and 8 can partly explain the increase in enzyme
w xactivity, in agreement with other findings 11,13–16 ,
and can be attributed to the increase in tyrosine
phosphorylation of the PDGFR induced by Ro-31-
 .8220 at later incubation times Figs. 1 and 5 . How-
ever, these changes are relatively small and the
changes in inositol phospholipids induced by the
 .inhibitor Table 1 suggest an additional explanation.
These data are consistent with a stimulatory effect of
Ro-31-8220 on the net synthesis of PtdInsP and
PtdInsP from PtdIns. Thus the enhanced formation2
of PtdInsP could provide additional substrate for2
PLC-g1. The mechanism of the effect of the inhibitor
is unknown, but could involve a stimulation of the
lipid kinases or an inhibition of the lipid phos-
phatases involved in the metabolism of the polyphos-
phoinositides. Since the effects of Ro-31-8220 could
not be mimicked by another potent and selective
 .PKC inhibitor, bIM Table 1 , they are probably not
attributable to inhibition of this enzyme. The failure
of bIM to alter the polyphosphoinositide levels also
indicates that such changes are not causally related to
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the inhibition of PLC-g1 tyrosine phosphorylation
induced by the PKC inhibitors.
A question of interest is the mechanism by which
Ro-31-8220 decreases tyrosine phosphorylation of
PLC-g1. The data of Figs. 1 and 2 and 5 indicate that
the inhibitor causes minimal changes in the intrinsic
tyrosine kinase activity of the PDGF receptor, but
almost totally inhibits the phosphorylation of PLC-g1.
Since the inhibitor did not block the association of
 .PLC-g1 with the receptor Figs. 4 and 7 or inhibit a
 .PDGF-activated soluble tyrosine kinase Fig. 3 , the
remaining possibilities are that it inhibits the phos-
phorylation of the enzyme by the receptor or acti-
vates a protein tyrosine phosphatase. However, such
an inhibition of phosphorylation or stimulation of
.dephosphorylation would have to be selective for
PLC-g1 since there was no consistent alteration of
the phosphorylation of other cellular proteins Figs. 1
.and 5 and data not shown . Such selectivity of action
of Ro-31-8220 on a tyrosine kinase or tyrosine phos-
phatase seems a priori unlikely. Another possibility is
that Ro-31-8220 inhibits a serinerthreonine kinase
that phosphorylates PLC-g1 and alters its ability to
serve as a substrate for a tyrosine kinase or tyrosine
.phosphatase . Again, it would have to be postulated
that such a kinase is selective for PLC-g1. The
possibility that Ro-31-8220 is selective because it
binds to PLC-g1 and alters its phosphorylation is
discounted by the lack of effect of the inhibitor in
 .vitro Fig. 3 .
 .The elucidation of the mechanism s of the effects
of Ro-31-8220 on PLC-g1 phosphorylation and poly-
phosphoinositide synthesis will take more work.
However, the results show very clearly that activation
of the enzyme by PDGF does not require its phos-
phorylation and support the hypothesis that associa-
tion with the receptor is sufficient for activation.
Additionally, the inositol phospholipid changes in-
duced by Ro-31-8220 indicate that caution should be
used in interpreting the effects of this compound on
responses that involve these phospholipids.
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